<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        105-10-12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VISANNE 2MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DIENOGEST
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        229.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAYER WEIMAR GmbH UND CO. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAYER WEIMAR GmbH UND CO. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 392]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-KAMAL IMPORT OFFICE CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03DB08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:-.1pt">Visanne is a preparation for the treatment of endometriosis (painful symptoms due to displaced tissue of the lining of the womb). Visanne contains a hormone, the progestogen dienogest.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>DO NOT take Visanne if you</strong>:</p><p>&nbsp;</p><p style="margin-left:17.0pt; text-indent:-17.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->are suffering from a <strong>blood clot</strong> (thromboembolic disorder) in your veins. This may occur, for example, in the blood vessels of the legs (deep vein thrombosis) or the lungs (pulmonary embolism). See also <em>&ldquo;Visanne and venous blood clots&rdquo; </em>below</p><p style="margin-left:17.0pt; text-indent:-17.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have or have ever had a <strong>severe arterial disease</strong>, including cardiovascular disease, such as a <strong>heart attack</strong>, <strong>stroke </strong>or <strong>heart disease</strong> which causes a reduced blood supply (angina pectoris). See also <em>&quot;Visanne and arterial blood clots&quot; </em>below</p><p style="margin-left:17.0pt; text-indent:-17.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have <strong>diabetes</strong> with blood vessel damage</p><p style="margin-left:17.0pt; text-indent:-17.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have or have ever had <strong>severe liver disease</strong> (and your liver function values have not returned to normal). Symptoms of liver disease may be yellowing of the skin and/or itching of the whole body</p><p style="margin-left:17.0pt; text-indent:-17.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have or have ever had a <strong>benign or malignant liver tumour</strong></p><p style="margin-left:17.0pt; text-indent:-17.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->suffer or have ever suffered, or if it is suspected that you suffer from a <strong>malignant</strong> sex-hormone dependent tumour such as cancer of the breast or the genital organs</p><p style="margin-left:17.0pt; text-indent:-17.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have any unexplained <strong>vaginal bleeding</strong></p><p style="margin-left:17.0pt; text-indent:-17.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->are <strong>allergic (hypersensitive) </strong>to dienogest or any of the other ingredients of this medicine <em>(see Section 6, and end of Section 2)</em></p><p>&nbsp;</p><p>If any of these conditions appear for the first time while using Visanne, stop taking it at once and consult your doctor.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt"><strong>Warnings and precautions</strong></p><p>You must not use hormonal contraceptives of any form (tablet, patch, intrauterine system) while taking Visanne.</p><p>&nbsp;</p><p>Visanne is NOT a contraceptive. If you want to prevent pregnancy, you should use condoms or other non-hormonal contraceptive precautions.</p><p>&nbsp;</p><p>In some situations you need to take special care while using Visanne, and your doctor may need to examine you regularly. Tell your doctor if any of the following conditions applies to you:</p><p>If you:</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ever had a <strong>blood clot</strong> (venous thromboembolism) or anyone in your immediate family has had a blood clot at a relatively early age</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have a close relative who has had <strong>breast cancer</strong></p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ever suffered from <strong>depression</strong></p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have <strong>high blood pressure</strong> or develop high blood pressure while taking Visanne</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->develop a <strong>liver disease</strong> while taking Visanne. Symptoms may include yellowing of the skin or eyes or itching all over your body. Inform your doctor also if such symptoms occurred during a previous pregnancy</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have diabetes or had <strong>diabetes</strong> temporarily during previous pregnancy</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ever had <strong>chloasma</strong> (golden-brown patches on the skin, particularly of the face); if so, avoid too much exposure to the sun or ultraviolet radiation</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->suffer from <strong>pain in your lower abdomen</strong> while taking Visanne.</p><p>&nbsp;</p><p>While taking Visanne your chance of becoming pregnant is reduced because Visanne may affect ovulation.</p><p>&nbsp;</p><p>If you become pregnant while taking Visanne you are at <strong>a slightly increased risk</strong> of having an extrauterine pregnancy (the embryo develops outside the womb). Tell your doctor before you start taking Visanne, if you had an extrauterine pregnancy in the past or have an impaired function of the Fallopian tubes.</p><p>&nbsp;</p><p><strong>Visanne and serious uterine bleeding</strong></p><p>&nbsp;</p><p>Uterine bleeding, for example in women with a condition where the mucous membrane of your uterus (endometrium) grows into the muscle layer of your uterus, called adenomyosis uteri or <strong>benign tumours of the womb </strong>sometimes called uterine fibroids<strong> </strong>(uterine leiomyomata), may become worse with the use of Visanne. If bleeding is heavy and continuous over time, this may lead to low red blood cell levels (anemia), which may be severe in some cases. In the event of anemia, you should discuss with your doctor if you should stop taking Visanne.</p><p>&nbsp;</p><p><strong>Visanne and changes in bleeding pattern</strong></p><p>&nbsp;</p><p>Most women treated with Visanne experience changes in their menstrual bleeding pattern (see section 4, possible side effects).</p><p>&nbsp;</p><p><strong>Visanne and venous blood clots</strong></p><p><strong>&nbsp;</strong></p><p>Some studies indicate that there may be a slight, but not statistically significant, increased risk of a <strong>blood clot in the legs (venous thromboembolism) </strong>associated with the use of preparations with progestagens like Visanne. Very rarely, blood clots may cause serious permanent disabilities or may even be fatal.</p><p>&nbsp;</p><p>The risk of a <strong>venous blood clot</strong> increases:</p><p>&nbsp;</p><ul><li>with increasing age</li><li>if you are overweight</li><li>if you or one of your close relatives had a blood clot in the leg (thrombosis), lung (pulmonary embolism), or other organ at a young age</li><li>if you must have surgery, if you have had a serious accident or if you are immobilized for a long time. It is important to tell your doctor in advance that you are using Visanne as the treatment may have to be stopped. Your doctor will tell you when to start Visanne again. This is usually about two weeks after you are back on your feet</li></ul><p style="margin-left:.25in; text-indent:-.25in">&nbsp;</p><p style="margin-left:.25in; text-indent:-.25in"><strong>Visanne and arterial blood clots</strong></p><p style="margin-left:.25in; text-indent:-.25in">&nbsp;</p><p>There is little evidence for an association between preparations with progestagens like Visanne and an increased risk of a blood clot in,&nbsp; for example, the bloodvessels of the heart (heart attack) or the brain (stroke). In women with hypertension the risk of stroke may be slightly enhanced by these preparations.</p><p>&nbsp;</p><p>&nbsp;</p><p>The risk of an <strong>arterial blood clot </strong>increases:</p><p>&nbsp;</p><ul><li><strong>if you smoke. You are strongly advised to stop smoking when you use Visanne, especially if you are older than 35 years.</strong></li><li>if you are overweight</li><li>if one of your close relatives had a heart attack or stroke at a young age</li><li>if you have high blood pressure</li></ul><p>&nbsp;</p><p>Talk to your doctor before taking Visanne.</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="height:168.8pt; vertical-align:top; width:488.95pt"><p><strong>Stop taking Visanne and contact your doctor immediately if you notice possible signs of a blood clot, such as:</strong></p><ul><li>severe pain and/or swelling in one of your legs</li><li>sudden severe pain in the chest which may reach the left arm</li><li>sudden breathlessness</li><li>sudden cough without an obvious cause</li><li>any unusual, severe or long-lasting headache or worsening of migraine</li><li>partial or complete blindness or double vision</li><li>difficulty in speaking or inability to speak</li><li>giddiness or fainting</li><li>weakness, strange feeling, or numbness in any part of the body</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Visanne and cancer</strong></p><p>&nbsp;</p><p>It is not clear from the data currently available whether or not Visanne increases the risk of breast cancer. Breast cancer has been observed slightly more often in women taking hormones compared to those not taking hormones, but it is not known whether this is caused by the treatment. For example, it may be that more tumours are detected and detected earlier in women taking hormones because they are examined by their doctor more often. The occurrence of breast tumours becomes gradually less after stopping the hormone treatment. <strong>It is important to regularly check your breasts</strong> and you should contact your doctor if you feel any lump.</p><p>&nbsp;</p><p>In rare cases, benign liver tumours, and in even fewer cases malignant liver tumours have been reported in women taking hormones. Contact your doctor if you have unusually severe stomach pain.</p><p>&nbsp;</p><p><strong>Visanne and osteoporosis</strong></p><p><strong><em>Changes in bone mineral density (BMD)</em></strong></p><p>The use of Visanne may affect the strength of the bone of adolescents (12 to under 18 years). If you are under 18 your doctor will, therefore, carefully weigh the benefits and risks of using Visanne for you as an individual patient, taking into account possible risk factors for bone loss (osteoporosis).</p><p style="margin-left:0in; margin-right:0in">If you use Visanne, it will help your bones if you have an adequate intake of calcium and</p><p style="margin-left:0in; margin-right:0in">vitamin D either via your food or via supplements.</p><p><strong><em>&nbsp;</em></strong></p><p>If you have an increased risk of getting osteoporosis (weakening of bones due to loss of bone minerals), your doctor will carefully weigh the risks and benefits of treatment with Visanne because Visanne has a moderate suppressing effect on the production of oestrogen (another type of female hormone) by your body.</p><p>&nbsp;</p><p style="margin-right:-.1pt"><strong>Other medicines and Visanne</strong></p><p style="margin-right:-.1pt">&nbsp;</p><p>Always tell your doctor which medicines or herbal products you are already using. Also tell any other doctor or dentist who prescribes another medicine (or the pharmacist) that you are taking Visanne.</p><p style="margin-right:-.1pt">&nbsp;</p><p>Some medicines can have an influence on the blood levels of Visanne and can make it less effective, or can cause undesirable effects.</p><p>These include:</p><ul><li>medicines used for the treatment of</li></ul><p style="margin-left:46.35pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&iexcl;&nbsp; <!--[endif]--><strong>epilepsy</strong> (e.g. phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate)</p><p style="margin-left:46.35pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&iexcl;&nbsp; <!--[endif]--><strong>tuberculosis (</strong>e.g. rifampicin<strong>)</strong></p><p style="margin-left:46.35pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&iexcl;&nbsp; <!--[endif]--><strong>HIV and Hepatitis C Virus infections</strong> (so-called protease inhibitors and non-nucleoside reverse transcriptase inhibitors such as ritonavir, nevirapine, efavirenz)</p><p style="margin-left:46.35pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&iexcl;&nbsp; <!--[endif]--><strong>fungal infections</strong> (griseofulvin, ketoconazole)</p><ul><li>the herbal remedy <strong>St. John&rsquo;s</strong> wort</li></ul><p><strong><em>&nbsp;</em></strong></p><p><em>Ask your doctor or pharmacist for advice before taking any medicine.</em></p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt"><strong>Visanne with food and drink</strong></p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">During Visanne treatment, you should avoid drinking grapefruit juice, because this may increase the levels of Visanne in your blood. This may increase the risk of getting side effects.</p><p style="margin-right:-.1pt">&nbsp;</p><p><strong>Laboratory tests</strong></p><p>&nbsp;</p><p>If you need a blood test, tell your doctor or the laboratory staff that you are taking Visanne, because Visanne can affect the results of some tests.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt"><strong>Pregnancy, breast-feeding and fertility</strong></p><p style="margin-right:-.1pt"><strong>&nbsp;</strong></p><p>Do not take Visanne if you are pregnant or breast-feeding.</p><p style="margin-right:-.1pt"><strong>&nbsp;</strong></p><p style="margin-right:-.1pt"><strong>Driving and using machines</strong></p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-1.45pt">No effects on the ability to drive and use machines have been observed in users of Visanne.</p><p>&nbsp;</p><p style="margin-right:-.1pt"><strong>Visanne contains lactose</strong></p><p style="margin-right:-.1pt"><strong>&nbsp;</strong></p><p style="margin-right:-.1pt">If you cannot tolerate certain sugars, please contact your doctor before you take Visanne.</p><p>&nbsp;</p><p style="margin-right:-.1pt"><strong>Children and adolescents</strong></p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">Visanne is not for use in girls before menarche (first menstrual bleeding).</p><p style="margin-right:-.1pt">The use of Visanne may affect the strength of the bone of adolescents (12 to under 18 years). If you are under 18 your doctor will, therefore, carefully weigh the benefits and risks of using Visanne for you as an individual patient, taking into account possible risk factors for bone loss (osteoporosis).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:-.1pt">Always take Visanne exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. For adults, the usual dose is 1 tablet per day.</p><p style="margin-right:-.1pt">&nbsp;</p><p>The following statements apply to Visanne unless otherwise prescribed by your doctor. Please follow these instructions, otherwise you will not fully benefit from Visanne.</p><p>&nbsp;</p><p>You can start treatment with Visanne on any day of your natural cycle.</p><p>&nbsp;</p><p>Adults: take one tablet every day, preferably at the same time with some liquid as needed. When a pack is finished the next one should be started without interruption. Continue to take the tablets also on days of menstrual bleeding.</p><p style="margin-right:-.1pt"><strong><em>&nbsp;</em></strong></p><p style="margin-right:-.1pt"><strong>If you take more Visanne than you should</strong></p><p>&nbsp;</p><p style="margin-right:-.1pt">There have been no reports of serious harmful effects from taking too many Visanne tablets at one time. However, if you are concerned, contact your doctor.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt"><strong>If you forget to take Visanne or suffer from vomiting or diarrhoea</strong></p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">Visanne will be less effective if you miss a tablet. If you miss one or more tablets, take one tablet only as soon as you remember, and then continue next day taking the tablet at your usual time.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">If you vomit within 3-4 hours of taking Visanne or you have severe diarrhoea, there is a risk that the active substance in the tablet will not be taken up by your body. The situation is almost the same as forgetting a tablet. After vomiting or diarrhoea within 3-4 hours of taking Visanne, you should take another tablet as soon as possible.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">Do not take a double dose to make up for a forgotten tablet.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt"><strong>If you stop taking Visanne</strong></p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">If you stop taking Visanne, your original endometriosis symptoms may return.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:-1.45pt">Like all medicines, Visanne can cause side effects, although not everybody gets them. These effects are more common during the first months after start of intake of Visanne and usually disappear with continued use. You may also experience changes in your bleeding pattern, such as spotting, irregular bleeding or your periods may stop completely.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt"><strong>Common (affecting between 1 and 10 in every 100 users)</strong></p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->weight gain</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->depressed mood, problems sleeping, nervousness, loss of interest in sex, or changed mood</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->headache or migraine</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->nausea, abdominal pain, wind, swollen tummy or vomiting</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->acne or hair loss</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->back pain</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->breast discomfort, ovarian cyst or hot flushes</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->uterine/vaginal bleeding including spotting</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->weakness or irritability</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt"><strong>&nbsp;</strong></p><p style="margin-right:-.1pt"><strong>Uncommon (affecting between 1 and 10 in every 1,000 users)</strong></p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->anemia</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->weight loss or increase in appetite</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->anxiety, depression or mood swings</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->imbalance in the autonomic nervous system (controls unconscious bodily functions, e.g. perspiration) or disturbed attention</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->dry eye</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->tinnitus</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->unspecific circulatory problems or uncommon palpitations</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->low blood pressure</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->shortness of breath</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->diarrhoea, constipation, abdominal discomfort, inflammation of the stomach and intestines (gastrointestinal inflammation), inflammation of the gums (gingivitis)</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->dry skin, excessive sweating, severe itching of the whole body, male pattern hair growth (hirsutism), brittle nails, dandruff, dermatitis, abnormal hair growth, hypersensitive response to light or problems with skin pigmentation</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pains in your bones, muscle spasms, pains and/or a sensation of heaviness in your arms and hands or legs and feet</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->urinary tract infection</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->vaginal thrush, dryness of the genital area, vaginal discharge, pelvic pain, atrophic inflammation of the genitals with discharge (atrophic vulvovaginitis), or a lump or lumps in the breast</p><p style="margin-left:.25in; margin-right:-.1pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling due to fluid retention</p><p>Additional side effects in adolescents (12 to under 18 years): loss of bone density.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt"><strong>Reporting of side effects</strong></p><p style="margin-right:-.1pt">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p style="margin-right:-.1pt">&nbsp;</p><table cellspacing="0" cellpadding="0" border="0"><thead><tr><td colspan="2" style="border-color:black; height:3.0pt; vertical-align:top; width:6.3in"><p style="margin-right:-.1pt"><strong>To report any side effect(s):</strong></p></td></tr></thead><tbody><tr><td style="border-color:black; height:3.0pt; vertical-align:top; width:219.75pt"><p style="margin-right:-.1pt"><strong>Saudi Arabia:</strong></p><p style="margin-right:-.1pt">The National Pharmacovigilance Centre (NPC).</p><p style="margin-right:-.1pt">SFDA Call Center: 19999</p><p style="margin-right:-.1pt">E-mail: npc.drug@sfda.gov.sa</p><p style="margin-right:-.1pt">Website: https://ade.sfda.gov.sa</p></td><td style="height:3.0pt; vertical-align:top; width:233.85pt"><p style="margin-right:-.1pt"><strong>Egypt:</strong></p><p style="margin-right:-.1pt">Egyptian Pharmaceutical Vigilance Centre</p><p style="margin-right:-.1pt">Tel.: +20 -225354100&nbsp;&nbsp; Ext.:1303</p><p style="margin-right:-.1pt">Email: pv.center@eda.mohealth.gov.eg</p></td></tr><tr><td style="border-color:black; height:3.0pt; vertical-align:top; width:219.75pt"><p style="margin-right:-.1pt"><strong>Oman:</strong></p><p style="margin-right:-.1pt">Tel: +968 - 2444 1999</p><p style="margin-right:-.1pt">Fax: +968 - 24602287</p><p style="margin-right:-.1pt">Email: pharma-vigil@moh.gov.om</p><p style="margin-right:-.1pt">Website: www.moh.gov.om</p></td><td style="height:3.0pt; vertical-align:top; width:233.85pt"><p style="margin-right:-.1pt"><strong>Jordan:</strong></p><p style="margin-right:-.1pt">Tel: +962-6-5632000</p><p style="margin-right:-.1pt">JFDA email : jpc@jfda.jo</p><p style="margin-right:-.1pt">JFDA website: www.jfda.jo</p><p style="margin-right:-.1pt">http://primaryreporting.who-umc.org/JO</p></td></tr><tr><td rowspan="2" style="border-color:black; height:20.55pt; vertical-align:top; width:219.75pt"><p style="margin-right:-.1pt"><strong>United Arab Emirates (UAE):</strong></p><p style="margin-right:-.1pt">Pharmacovigilance &amp; Medical Device section</p><p style="margin-right:-.1pt">Tel: 80011111 /</p><p style="margin-right:-.1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +971 42301000&nbsp;</p><p style="margin-right:-.1pt">Email: pv@mohap.gov.ae</p><p style="margin-right:-.1pt">Website: www.mohap.gov.ae</p><p style="margin-right:-.1pt">P.O.Box 1853 Dubai</p></td><td style="height:20.55pt; vertical-align:top; width:233.85pt"><p style="margin-right:-.1pt"><strong>Kuwait:</strong></p><p style="margin-right:-.1pt">Hotline: 1810005</p><p style="margin-right:-.1pt">Email: health@moh.gov.kw</p><p style="margin-right:-.1pt">Website: www.moh.gov.kw/kdfc/</p><p style="margin-right:-.1pt">P.O.Box: 5 Safat, 13001 Kuwait</p></td></tr><tr><td style="height:20.55pt; vertical-align:top; width:233.85pt"><p style="margin-right:-.1pt"><strong>Other Countries:</strong></p><p style="margin-right:-.1pt">Please contact the relevant competent authority</p></td></tr></tbody></table><p style="margin-right:-.1pt"><strong>&nbsp;</strong></p><p style="margin-right:-.1pt"><strong>&nbsp;</strong></p><p style="margin-right:-.1pt"><strong>&nbsp;</strong></p><p style="margin-right:-.1pt"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:-.1pt">Store in the original packaging to protect from light.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">Do not store above 30˚C.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">Keep out of the sight and reach of children.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">Do not use this medicine after the expiry date which is stated on the packaging after &ldquo;Do not use after:&rdquo; or &ldquo;EXP.:&rdquo;</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">The expiry date refers to the last day of that month.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:-.1pt"><strong>What Visanne contains</strong></p><p style="margin-right:-.1pt"><u>&nbsp;</u></p><p style="margin-right:-.1pt">The active substance is dienogest. Each tablet contains 2 mg dienogest.</p><p style="margin-right:-.1pt"><em>&nbsp;</em></p><p>The other ingredients are lactose monohydrate, potato starch, microcrystalline cellulose, povidone K 25, talc, crospovidone, magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Visanne looks like and contents of the pack
	
	Visanne tablets are white to off-white, round flat-faced bevelled-edged with a debossed “B” on one side and a diameter of 7 mm.
	
	They are supplied in a blister pack containing 14 tablets.
	
	Boxes contain blister packs with 28 (2x14) or 84 (6x14) tablets.
	
	Not all pack sizes may be marketed

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:-.1pt"><strong>Manufacturer</strong></p><p>Bayer&nbsp; Weimar GmbH &amp; Co KG</p><p>99427 Weimar, Germany.</p><p style="margin-right:-.1pt">&nbsp;</p><p style="margin-right:-.1pt">M<strong>arketing Authorisation Holder</strong></p><p style="margin-right:-.1pt">Bayer AG</p><p style="margin-right:-.1pt">Leverkusen, Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in April 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="text-align:right">فيزان مستحضر لعلاج الإنتباذ البطاني الرحمي (أعراض مؤلمة بسبب إزاحة النسيج المبطن للرحم). يحتوي فيزان على هرمون، بروجستيروني المفعول داينوجست.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>لا تتناولي فيزان إذا كنت:</strong></p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تعاني من <strong>جلطة دموية</strong> (إضطراب إنصمام خثاري) في الأوردة. هذا يمكن أن يحدث، مثلاً، في الأوعية الدموية للسيقان (خثار وريدي عميق) أو الرئة (إنصمام رئوي). أنظر أيضاً &ldquo;<strong>فيزان و الجلطات الدموية الوريدية</strong>&rdquo; بأسفل</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لديك الآن أو كان لديك في أي وقت مضى <strong>مرض شرياني شديد</strong>، يتضمن مرض قلبي وعائي، مثل <strong>نوبة قلبية، سكتة أو مرض قلبي</strong> الذي يسبب إنخفاض للإمداد الدموي (ذبحة صدرية). انظر أيضاً &laquo;<strong>فيزان و الجلطات الدموية الشريانية</strong>&raquo; بأسفل</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لديك <strong>الداء السكري</strong> مع ضرر لللأوعية الدموية</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لديك الآن أو كان لديك في أي وقت مضى <strong>مرض شديد للكبد</strong> (و قيم وظائف الكبد لم تعد لطبيعتها). أعراض مرض الكبد يمكن أن تكون إصفرار لون الجلد و / أو حكة للجسم بالكامل</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لديك الآن أو كان لديك في أي وقت مضى <strong>ورم حميد أو خبيث في الكبد</strong></p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تعاني الآن أو عانيت في الماضي، أو يشتبه أنك تعاني من ورم <strong>خبيث</strong> يعتمد على الهرمون الجنسي مثل سرطان الثدي أو الأعضاء التناسلية</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لديك أي <strong>نزف مهبلي</strong> بدون تفسير</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لديك <strong>أرجية (حساسية زائدة) </strong>لداينوجست أو لأي من المكونات الأخرى لهذا الدواء (<strong>أنظر الجزء 6، و نهاية الجزء 2</strong>)</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا ظهرت أي من هذه الحالات للمرة الأولى أثناء تناول فيزان، توقفي فوراً عن تناوله و إستشيري طبيبك.</p><p dir="RTL" style="text-align:right"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL" style="text-align:right">يجب أن لا تستخدمي أثناء تناولك فيزان أي موانع حمل هرمونية من أي شكل (قرص، لطخة، جهاز داخل الرحم). فيزان <strong>ليس</strong> مانع للحمل. إذا كنت تريدي منع الحمل، يجب إستخدام عوازل ذكرية أو إحتياطات أخرى مانعة للحمل غير هرمونية. في بعض المواقف تحتاجى لإتخاذ عناية خاصة أثناء تناول فيزان، و يمكن أن يحتاج طبيبك لفحصك بإنتظام. أبلغي طبيبك إذا كانت أي من الحالات الآتية تنطبق عليك: إذا أنت:</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->كان لديك في أي وقت مضى <strong>جلطة دموية</strong> (انصمام خثاري وريدي) أو كان لأي شخص من أفراد العائلة&nbsp; المباشرة لديه جلطة دموية في سن مبكر نسبياً</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لديك إحدى الأقارب المقربين كان لديها <strong>سرطان الثدي</strong></p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->كنت تعاني في أي وقت مضى من <strong>إكتئاب</strong></p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لديك <strong>ضغط دم مرتفع </strong>أو أصبح لديك ضغط دم مرتفع أثناء تناول فيزان</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تكون لديك <strong>مرض للكبد</strong> أثناء تناول فيزان. الأعراض يمكن أن تشمل تلون الجلد أو العيون باللون الأصفر أو حكة للجسم بالكامل. إخطري طبيبك إذا كانت مثل هذه الأعراض حدثت أثناء فترة حمل سابقة.</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لديك <strong>الداء السكري</strong> أو كان لديك في الماضي داء سكري مؤقت أثناء فترة حمل سابقة</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->كان لديك في أي وقت مضى <strong>كلف</strong> (لطخات بنية ذهبية اللون على الجلد، خاصة في الوجه)؛ إذا حدث ذلك، تجنبي التعرض بكثرة للشمس أو الأشعة الفوق بنفسجية</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تعاني من<strong> ألم في أسفل البطن</strong> أثناء تناول فيزان.</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إمكانية أن تصبحي حامل أثاء تناول فيزان تنخفض لأن فيزان يمكن أن يؤثر في التبويض. إذا أصبحت حامل بينما تتناولين فيزان، <strong>فمخاطرة الحمل خارج الرحم تكون مرتفعة قليلاً </strong>(نمو الجنين خارج الرحم). إخطري طبيبك قبل بداية تناولك فيزان، إذا كان لديك في الماضي حمل خارج الرحم أو كان لديك خلل وظيفي للبوق الرحمي .</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>فيزان و النزف الرحمي الشديد</strong></p><p dir="RTL" style="text-align:right">يمكن للنزف الرحمي أن يصبح أسوأ مع تناول فيزان، مثلاً في سيدات لديهن حالة بها الغشاء المخاطي للرحم (بطانة الرحم) تنمو داخل الطبقة العضلية للرحم، التي تسمى عضال غدي رحمي أو لديهن <strong>أورام حميدة للرحم</strong> تسمى أحياناً الليفانيات الرحمية (ورم عضلي أملس رحمي). إذا كان النزف شديد و مستمر لمدة طويلة من الوقت، يمكن أن يؤدي ذلك إلى مستويات منخفضة لخلايا الدم الحمراء (فقر دم)، الذي يمكن في بعض الحالات أن يكون شديد. في حالة فقر الدم، يجب مناقشة ذلك مع طبيبك إذا كان يجب عليك التوقف عن تناول فيزان.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>فيزان و تغيرات في نمط النزف</strong></p><p dir="RTL" style="text-align:right">معظم السيدات الآتي تم معالجتهن بفيزان عانوا من تغيرات في نمط نزفهم الحيضي (أنظر الجزء 4، الآثار الجانبية المحتملة).</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>فيزان و الجلطات الدموية الوريدية</strong></p><p dir="RTL" style="text-align:right">تشير بعض الدراسات أنه يمكن أن تزداد قليلاً، لكن غير معتد بها إحصائياً، لمخاطرة <strong>الجلطة الدموية في السيقان (إنصمام خثاري وريدي)</strong> المصاحب لتناول مستحضرات تحتوي على مادة بروجستيرونية المفعول مثل فيزان. نادراً جداً، يمكن أن تسبب الجلطات الدموية عجز خطير مستمر أو حتى يمكن أن يكون مميت.</p><p dir="RTL" style="text-align:right">تزداد مخاطرة<strong> الجلطة الدموية الوريدية:</strong></p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مع زيادة العمر</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان لديك زيادة للوزن</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت أنت أو أحد أقربائك المقربين تم إصابته في عمر صغير بجلطة دموية في الساق (خثار)، الرئة (إنصمام رئوي)، أو لعضو آخر</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان يجب إجراء عملية جراحية، إذا كان لديك حادث خطير أو عدم الحركة لوقت طويل. من المهم إخطار طبيبك مسبقاً أنك تتناولي فيزان لأنه يمكن أن يطلب منك أن توقفي العلاج. سوف يخطرك طبيبك متى تبدئي مرة أخرى تناول فيزان. هذا عادة يكون بعد أسبوعين تقريباً بعد العودة للسير على قدميك.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>فيزان و الجلطات الدموية الشريانية</strong></p><p dir="RTL" style="text-align:right">يوجد دليل صغير لعلاقة بين مستحضرات بها مادة بروجستيرونية المفعول مثل فيزان و زيادة مخاطرة الجلطة الدموية في، مثلاً، الأوعية الدموية للقلب (نوبة قلبية) أو الدماغ (سكتة). في السيدات بضغط دم مرتفع مخاطرة السكتة يمكن أن تزداد قليلاً بهذه المستحضرات.</p><p dir="RTL" style="text-align:right">تزداد مخاطرة <strong>الجلطة الدموية الشريانية</strong>:</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>إذا كنت مدخنة. نحذر بشدة أنه يجب التوقف عن التدخين عند تناول فيزان، خاصة إذا كان العمر أكثر من 35 سنة.</strong></p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان لديك وزن زائد</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان أحد أقربائك المقربين تم إصابته بنوبة قلبية أو بسكتة في عمر صغير</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان لديك ضغط دم مرتفع</p><p dir="RTL" style="text-align:right">تحدثي إلى طبيبك قبل استخدام فيزان</p><p dir="RTL" style="text-align:right"><strong>توقفي عن تناول فيزان و إتصلي بطبيبك فوراً إذا لاحظتي علامات محتملة لجلطة دموية، مثل:</strong></p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم شديد و / أو تورم في أحد السيقان</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم شديد مفاجئ في الصدر الذي يمكن أن يصل للذراع الأيسر.</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضيق التنفس المفاجئ</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سعال مفاجئ بدون سبب واضح</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->أي صداع غير عادي، شديد أو يستمر لفترة طويلة أو اشتداد الصداع النصفى (الشقيقة)</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عمى جزئي أو تام أو رؤية مزدوجة</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->صعوبة الكلام أو عدم المقدرة على الكلام</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->دوخة أو إغماء</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضعف، شعور غريب، أو تنميل (خدر) في أي جزء من الجسم</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>فيزان و السرطان</strong></p><p dir="RTL" style="text-align:right">غير واضح من البيانات المتوفرة حالياً ما إذا كان فيزان يزيد أو لا يزيد مخاطرة سرطان الثدي. تم ملاحظة أن سرطان الثدي نسبيا أكثر قليلاً لدى سيدات تتناولن هرمونات إذا تم مقارنتهن بسيدات لا تتناول هرمونات، و لكن غير معروف ما إذا كان هذا بسبب العلاج. مثلاً، يمكن أن الأورام تكتشف أكثر و تكتشف مبكراً في سيدات تتناول الهرمونات بسبب أن فحصهن من الطبيب يحدث في أحوال كثيرة أكثر. حدوث أورام الثدي يصبح أقل تدريجياً بعد التوقف عن العلاج الهرموني. <strong>من المهم فحص الثدي بإنتظام</strong> و يجب الإتصال بطبيبك إذا شعرتي بأي كتلة.</p><p dir="RTL" style="text-align:right">تم التبليغ في حالات نادرة، لأورام حميدة بالكبد، و حتى في حالات نادرة أكثر لأورام خبيثة لدى سيدات تتناولن الهرمونات. إتصلي بطبيبك إذا كان لديك ألم شديد غير معتاد بالمعدة.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>فيزان و هشاشة العظم</strong></p><p dir="RTL" style="text-align:right"><em><u>التغيرات في كثافة المعادن في العظام </u></em>(BMD)</p><p dir="RTL" style="text-align:right">استخدام فيزان قد يؤثر على قوة العظام من المراهقين (12 إلى أقل من 18 سنة). إذا كنت أقل سن 18 فإن طبيبك سوف يوازن بعناية بين فوائد ومخاطر استخدام فيزان بالنسبة لحالتك، مع الأخذ بعين الاعتبار عوامل الخطر المحتمل لفقدان العظام (هشاشة العظام).</p><p dir="RTL" style="text-align:right">إذا كنت تستخدم فيزان، سوف يساعد عظامك في هذه الحالة أن يتوفر لديك كمية كافية من الكالسيوم وفيتامين D إما عن طريق الغذاء أو المكملات الغذائية</p><p dir="RTL" style="text-align:right">إذا كان لديك مخاطرة زائدة للإصابة بهشاشة العظم (ضعف العظام بسبب فقدان معادن العظام)، سوف يوازن طبيبك بعناية المخاطر و الفوائد من العلاج بفيزان لأن فيزان لديه أثر مثبط معتدل على إنتاج الإستروجين (نوع آخر من الهرمون الأنثوي) من الجسم.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>أدوية أخرى و فيزان</strong></p><p dir="RTL" style="text-align:right">دائماً إخطري طبيبك عن أي أدوية أو مستحضرات عشبية تتناوليها بالفعل. أيضاً إخطري أي طبيب آخر أو طبيب أسنان الذي يوصف لك أدوية أخرى (أو الصيدلي) أنك تتناولي فيزان.</p><p dir="RTL" style="text-align:right">قد يكون لبعض الأدوية تأثير على مستويات فيزان في الدم ويمكن أن تجعل منه أقل فاعلية، أو يمكن أن تتسبب في آثار غير مستحبة.</p><p dir="RTL" style="text-align:right">و هذه تشمل:</p><p dir="RTL" style="text-align:right">أدوية يتم تناولها لعلاج الآتي</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>الصرع</strong> (مثل فنيتوين، بربيتيوريت، بريميدون، كاربامازبين، اوكساكاربازبين، توبيراميت، فلباميت)</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>الدرن</strong> (مثل ريفامبسين)</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>إصابات فيروس نقص المناعة البشرية (الإيدز) والعدوى بفيروس </strong><strong>C</strong><strong>&nbsp; التهاب الكبد الوبائي</strong> (المسماة مثبطات الأنزيم البروتيني و مثبطات إنزيم النسخ العكسي الغير نيوكليوسيد مثل ريتونافير، نيفيرابين، ايفافيرنز)</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>الالتهابات الفطرية</u> (غريزيوفولفين، الكيتوكونازول)</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->العلاج العشبي عشبة <strong>سان جون</strong></p><p dir="RTL" style="text-align:right"><strong>أطلبي نصيحة طبيبك أو الصيدلي قبل تناول أي أدوية.</strong></p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>فيزان مع الغذاء و الشراب</strong></p><p dir="RTL" style="text-align:right">خلال فترة العلاج بفيزان، يجب تجنب شرب عصير الجريب فروت، لأن هذا قد يزيد من مستويات الفيزان&nbsp; في دمك. مما قد يزيد من خطر الإصابة بآثار جانبية</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>الإختبارات المعملية</strong></p><p dir="RTL" style="text-align:right">إذا كنت تحتاجين لإختبار دم، إخطري طبيبك أو هيئة المعمل إنك تتناولي فيزان، لأن فيزان يمكن أن يؤثر في نتائج بعض الإختبارات.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>الحمل و الرضاعة الطبيعية</strong></p><p dir="RTL" style="text-align:right">لا تتناولي فيزان إذا كنت حامل أو ترضعين طبيعياً.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>القيادة و تشغيل الماكينات</strong></p><p dir="RTL" style="text-align:right">لم يتم ملاحظت آثار على قدرة القيادة و على تشغيل الماكينات في من يتناولوا فيزان.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>يحتوي فيزان على لاكتوز</strong></p><p dir="RTL" style="text-align:right">إذا كنت لا تستطيعين تحمل سكريات معينة، يرجى الاتصال بطبيبك قبل تناول فيزان.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>الاطفال والمراهقات </strong></p><p dir="RTL" style="text-align:right">فيزان ليس للاستخدام في الفتيات قبل الدورة الشهرية (نزيف الحيض الأول)</p><p dir="RTL" style="text-align:right">قد يؤثر استخدام فيزان على قوة العظام للمراهقين (12 الى 18 سنة). إذا كنت أقل من سن 18 فإن طبيبك سوف يوازن بعناية بين فوائد ومخاطر استخدام فيزان بالنسبة لحالتك، مع الأخذ بعين الاعتبار عوامل الخطر المحتمل لفقدان العظام (هشاشة العظام).</p><p dir="RTL" style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">دائماً تناولي فيزان تماماً كما أخبرك طبيبك. يجب مراجعة طبيبك أو الصيدلي إذا كنت غير متأكدة. للبالغين، الجرعة المعتادة هي 1 قرص في اليوم. البيانات الآتية تنطبق على فيزان إلا إذا وصف طبيبك خلاف ذلك. رجاء إتباع هذه التعليمات، لأن خلاف ذلك لن تستفيدي بالكامل من فيزان.</p><p dir="RTL" style="text-align:right">يمكن أن تبدئي العلاج مع فيزان في أي يوم من الدورة الشهرية الطبيعية الخاصة بك.</p><p dir="RTL" style="text-align:right">البالغين: تناولي قرص واحد كل يوم، يفضل في نفس الوقت مع بعض السائل كما تحتاجين. عندما تنتهي عبوة يجب البدأ بالعبوة التالية بدون توقف. إستمري في تناول الأقراص أيضاً في أيام النزف الحيضي.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>إذا تناولت فيزان أكثر مما يجب</strong></p><p dir="RTL" style="text-align:right">لا توجد تقارير عن آثار ضارة خطيرة من تناول أقراص كثيرة مرة واحدة من فيزان. مع ذلك، إذا كنت معنية، إتصلي بطبيبك.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>إذا نسيت تناول فيزان أو تعاني من قيئ أو إسهال</strong></p><p dir="RTL" style="text-align:right">سوف تقل فاعلية فيزان إذا نسيت قرص. إذا نسيت قرص واحد أو أكثر من قرص، تناولي قرص واحد فقط في أسرع وقت تذكرتي فيه، ثم إستمري اليوم التالي في تناول القرص في الوقت المعتاد.</p><p dir="RTL" style="text-align:right">إذا حدث قيئ خلال 3 &ndash; 4 ساعات من تناول فيزان أو حدث إسهال شديد، توجد مخاطرة أن المادة الفعالة في القرص لن يتم امتصاصها بالكامل داخل جسمك. الموقف مماثل لحالة نسيان قرص. بعد القيئ أو الإسهال خلال 3 &ndash; 4 ساعات من تناول فيزان، يجب تناول قرص آخر في أقرب وقت ممكن. لا تتناولي جرعة مضاعفة لتعويض قرص تم نسيانه.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>إذا توقفت عن تناول فيزان</strong></p><p dir="RTL" style="text-align:right">إذا توقفت عن تناول فيزان، يمكن لأعراض الإنتباذ البطاني الرحمي أن تعود كما كانت في الأصل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">مثل كل الأدوية، يمكن لفيزان أن يسبب آثار جانبية، بالرغم من أنها لا تحدث مع كل شخص. هذه الآثار أكثر إعتياداً خلال الشهور الأولى بعد بداية تناول فيزان و عادة تختفي مع إستمرار التناول. يمكن أيضاً أن تعاني تغيرات في نمط النزف، مثل التبقيع، النزف الغير منتظم أو يمكن للدورات الشهرية (الحيض) أن تتوقف تماماً.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>شائع: (يصيب من 1 إلى 10 من كل 100 مستخدمة)</strong></p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->زيادة الوزن</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مزاج مكتئب، مشاكل في النوم، عصبية، فقدان الإهتمام بالجنس، أو مزاج متغير</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->صداع أو شقيقة</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->غثيان، آلم في البطن، غازات، إنتفاخ&nbsp; البطن أو قيئ</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->حب الشباب أو فقدان الشعر</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم الظهر</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم فى الثدي، كيسة بالمبيض أو إحمرار الوجه و العنق العابر الساخن</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->نزف رحمي / مهبلي يشمل التبقيع</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضعف أو تهيج</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>غير شائع (يصيب من 1 إلى 10 من كل 1.000 مستخدمة)</strong></p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فقر دم</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فقدان الوزن أو زيادة في شهية</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قلق، اكتئاب أو مزاج متأرجح</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عدم إتزان في الجهاز العصبي الأوتونومي (مراقبة وظائف الجسم اللاشعورية، مثل التعرق) أو إضطراب الإنتباه</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->جفاف العين</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->طنين</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مشاكل غير محددة للدورة الدموية أو خفقان غير شائع</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضغط دم منخفض</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضيق النفس</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إسهال، إمساك، ألم بالبطن، إلتهاب في المعدة و الأمعاء (إلتهاب معدي معوي)، إلتهاب اللثة (التهاب اللثة)</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->جفاف الجلد، زيادة العرق، حكة شديدة للجسم بالكامل، نمط ذكري لنمو الشعر (زبب)، أظافير سريعة الإنكسار (هشة)، قشرة الرأس، إلتهاب الجلد، نمو شعر غير طبيعي، فرط الحساسية للإستجابة للضؤ أو مشاكل مع تصبغ الجلد</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألام في العظام، تشنجات للعضلات، ألآم و / أو إحساس بثقل في الأذرع و الأيدي و السيقان و الأرجل</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عدوى المسالك البولية</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سلاق المهبل، جفاف منطقة المهبل، إفرازات مهبلية، ألم حوضي، التهاب ضموري للأعضاء التناسلية مع إفرازات (إلتهاب ضموري&nbsp; للفرج و المهبل)، أو كتلة أو كتل في الثدي</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تورم بسبب إحتباس السائل</p><p dir="RTL" style="text-align:right">اثار جانبية اضافية في المراهقين (12 إلى أقل من 18 سنة): فقدان كثافة العظام</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL" style="text-align:right">إذا أصبت بأي أعراض جانبية، تحدث مع طبيبك أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة وغير مذكورة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك أن تساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><table cellspacing="0" cellpadding="0" border="0"><thead><tr><td colspan="2" style="border-color:black; height:17.5pt; vertical-align:top; width:496.75pt"><p dir="RTL" style="text-align:right"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p></td></tr></thead><tbody><tr><td style="border-color:black; height:17.0pt; vertical-align:top; width:247.6pt"><p dir="RTL" style="text-align:right"><strong>السعودية:</strong></p><p dir="RTL" style="text-align:right">المركز الوطني للتيقظ الدوائي</p><p dir="RTL" style="text-align:right">مركز اتصال الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL" style="text-align:right">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL" style="text-align:right">الموقع الالكتروني: https://ade.sfda.gov.sa</p></td><td style="height:17.0pt; vertical-align:top; width:249.15pt"><p dir="RTL" style="text-align:right"><strong>مصر:</strong></p><p dir="RTL" style="text-align:right">مركز اليقظة الصيدلية المصري</p><p dir="RTL" style="text-align:right">هاتف: 225354100 - 20+&nbsp;&nbsp;&nbsp;</p><p dir="RTL" style="text-align:right">تحويلة: 1303</p><p dir="RTL" style="text-align:right">البريد الالكتروني: pv.center@eda.mohealth.gov.eg</p></td></tr><tr><td style="border-color:black; height:51.15pt; vertical-align:top; width:247.6pt"><p dir="RTL" style="text-align:right"><strong>الإمارات العربية المتحدة:</strong></p><p dir="RTL" style="text-align:right">قسم التيقظ الدوائي والأجهزة الطبية</p><p dir="RTL" style="text-align:right">هاتف: 80011111 / 42301000 &ndash; 971+</p><p dir="RTL" style="text-align:right">البريد الاكتروني: pv@mohap.gov.ae</p><p dir="RTL" style="text-align:right">الموقع الالكتروني: www.mohap.gov.ae</p><p dir="RTL" style="text-align:right">ص.ب. 1853 دبي</p></td><td style="height:51.15pt; vertical-align:top; width:249.15pt"><p dir="RTL" style="text-align:right"><strong>الأردن:</strong></p><p dir="RTL" style="text-align:right">هاتف: 5632000-6-962+</p><p dir="RTL" style="text-align:right">البريد الالكتروني: jpc@jfda.jo</p><p dir="RTL" style="text-align:right">الموقع الالكتروني: www.jfda.jo</p><p dir="RTL" style="text-align:right">http://primaryreporting.who-umc.org/JO</p></td></tr><tr><td style="border-color:black; height:17.1pt; vertical-align:top; width:247.6pt"><p dir="RTL" style="text-align:right"><strong>الكويت:</strong></p><p dir="RTL" style="text-align:right">الخط الساخن: 1810005</p><p dir="RTL" style="text-align:right">البريد الاكتروني: health@moh.gov.kw</p><p dir="RTL" style="text-align:right">الموقع الالكتروني: &nbsp;www.moh.gov.kw/kdfc/</p><p dir="RTL" style="text-align:right">ص.ب: 5 صفاة، 13001 الكويت</p></td><td style="height:17.1pt; vertical-align:top; width:249.15pt"><p dir="RTL" style="text-align:right"><strong>سلطنة عمان:</strong></p><p dir="RTL" style="text-align:right">هاتف: 24441999 &ndash; 968+</p><p dir="RTL" style="text-align:right">فاكس: 24602287 &ndash; 968+</p><p dir="RTL" style="text-align:right">البريد الالكتروني: pharma-vigil@moh.gov.om</p><p dir="RTL" style="text-align:right">الموقع الالكتروني: www.moh.gov.om</p></td></tr><tr><td colspan="2" style="border-color:black; height:3.0pt; vertical-align:top; width:496.75pt"><p dir="RTL" style="text-align:right"><strong>بلدان أخرى:</strong></p><p dir="RTL" style="text-align:right">يرجى الاتصال بالسلطة المختصة ذات الصلة.</p></td></tr></tbody></table><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">يحفظ في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL" style="text-align:right">يحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p dir="RTL" style="text-align:right">يحفظ بعيداً عن متناول نظر أو أيدي الأطفال.</p><p dir="RTL" style="text-align:right">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد &laquo;لا يُستخدم بعد: &raquo; أو &laquo;EXP&raquo;. تاريخ الانتهاء يشير إلى آخر يوم من الشهر المذكور.</p><p dir="RTL" style="text-align:right">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعود تستخدمها. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>ماذا يحتوي فيزان</strong></p><p dir="RTL" style="text-align:right">المادة الفعالة داينوجست. كل قرص يحتوي على 2 ميليغرام داينوجست.</p><p dir="RTL" style="text-align:right">المركبات الأخرى هي مونوهيدرات اللاكتوز، نشاء البطاطس، بلورات سيللولوز متناهية الصغر،&nbsp; بوفيدون K25، تلك، كروسبوفيدون، ستيارات المغنيزيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>ما هو مظهر فيزان و ما هي محتويات العبوة:</strong></p><p dir="RTL" style="text-align:right">أقراص فيزان بيضاء لأبيض مصفر مستديرة مسطحة الوجه المشطوف ذات حدين مع نقوش &laquo;B&raquo; على أحد الجوانب و قطر القرص 7 ميليمتر.</p><p dir="RTL" style="text-align:right">متوفر في عبوة شريط تحتوي على 14 قرص.</p><p dir="RTL" style="text-align:right">تحتوي العلب عبوات شرائط بها 28 (2 &times; 14) أو 84 (6 &times; 14) قرص.</p><p dir="RTL" style="text-align:right">لا يتم تسويق كل أحجام العبوة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>المصنع</strong></p><p dir="RTL" style="text-align:right">باير فايمر جي أم بي اتش أند كو كي جي</p><p dir="RTL" style="text-align:right">99427 فايمر، ألمانيا.</p><p dir="RTL" style="text-align:right"><strong>الحاصل على ترخيص التسويق:</strong></p><p dir="RTL" style="text-align:right">باير ايه جي</p><p dir="RTL" style="text-align:right">ليفركوزن، ألمانيا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في أبريل 2020.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Visanne 2 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 2 mg dienogest

Excipient with known effect: each tablet contains 62.8 mg lactose monohydrate.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets

White to off-white, round, flat-faced, bevelled-edge tablets with a debossed “B” on one side and a diameter of 7 mm.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of endometriosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Method of administration:</u></em></p><p>&nbsp;</p><p>For oral use.</p><p>&nbsp;</p><p><em><u>Posology</u></em></p><p>&nbsp;</p><p>The dosage of Visanne is one tablet daily without any break, taken preferably at the same time each day with some liquid as needed. The tablet can be taken with or without food.</p><p>&nbsp;</p><p>Tablets must be taken continuously without regard to vaginal bleeding. When a pack is finished the next one should be started without interruption.</p><p>&nbsp;</p><p>Treatment can be started on any day of the menstrual cycle.</p><p>&nbsp;</p><p>Any hormonal contraception needs to be stopped prior to initiation of Visanne. If contraception is required, non-hormonal methods of contraception should be used (e.g. barrier method).</p><p>&nbsp;</p><p><em><u>Management of missed tablets:</u></em></p><p>The efficacy of Visanne may be reduced in the event of missed tablets, vomiting and/or diarrhea (if occuring within 3-4 hours after tablet taking). In the event of one or more missed tablets, the woman should take one tablet only, as soon as she remembers, and should then continue the next day at her usual time. A tablet not absorbed due to vomiting or diarrhea should likewise be replaced by one tablet.</p><p>&nbsp;</p><p><strong><em><u>Additional information on special populations</u></em></strong></p><p>&nbsp;</p><p><em><u>Paediatric population</u></em><strong><em>:</em></strong></p><p>Visanne is not indicated in children prior to menarche</p><p>&nbsp;</p><p>The safety and efficacy of Visanne was investigated in an uncontrolled clinical trial over 12 months in 111 adolescent women (12-&lt;18) with clinically suspected or confirmed endometriosis (see sections 4.4 and 5.1).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Geriatric population</u></em><em>:</em></p><p>There is no relevant indication for use of Visanne in the Geriatric population.</p><p>&nbsp;</p><p><em><u>Patients with hepatic impairment</u></em><em>:</em></p><p>Visanne is contraindicated in patients with present or past severe hepatic disease (see section 4.3).</p><p>&nbsp;</p><p><em><u>Patients with renal impairment</u></em><em>:</em></p><p>There are no data suggesting the need for a dosage adjustment in patients with renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Visanne should not be used in the presence of any of the conditions listed below, which are partially derived from information on other progesteron-only preparations. Should any of the conditions appear during the use of Visanne, treatment must be discontinued immediately.

•	active venous thromboembolic disorder
•	arterial and cardiovascular disease, past or present (e.g. myocardial infarction, cerebrovascular accident, ischemic heart disease)
•	diabetes mellitus with vascular involvement
•	presence or history of severe hepatic disease as long as liver function values have not returned to normal 
•	presence or history of liver tumours (benign or malignant)
•	known or suspected sex hormone-dependent malignancies 
•	undiagnosed vaginal bleeding 
•	hypersensitivity to the active substance or to any of the excipients listed in Section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Warnings</strong></p><p>&nbsp;</p><p>As Visanne is a progestogen-only preparation it can be assumed that the special warnings and precautions for use of progestogen-only preparations are also valid for the use of Visanne although not all of the warnings and precautions are based on respective findings in the clinical studies with Visanne.</p><p>&nbsp;</p><p>If any of the conditions/risk factors mentioned below is present or deteriorates, an individual risk-benefit analysis should be done before treatment with Visanne can be started or continued.</p><p>&nbsp;</p><p style="margin-left:.25in; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Serious uterine bleeding</u></em></p><p>&nbsp;</p><p>Uterine bleeding, for example in women with adenomyosis uteri or uterine leiomyomata, may be aggravated with the use of Visanne. If bleeding is heavy and continuous over time, this may lead to anemia (severe in some cases). In the event of anemia, discontinuation of Visanne should be considered.</p><p>&nbsp;</p><p style="margin-left:.25in; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Changes in bleeding pattern</u></em></p><p>&nbsp;</p><p>The majority of patients treated with Visanne experience changes in their menstrual bleeding pattern (see section 4.8).</p><p>&nbsp;</p><p style="margin-left:.25in; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Circulatory disorders</u></em></p><p style="margin-left:.25in; margin-right:0in"><em><u>&nbsp;</u></em></p><p>From epidemiological studies there is little evidence for an association between progestogen-only preparations and an increased risk of myocardial infarction or cerebral thromboembolism. Rather, the risk of cardiovascular and cerebral events is related to increasing age, hypertension, and smoking. In women with hypertension the risk of stroke may be slightly enhanced by progestogen-only preparations.</p><p>&nbsp;</p><p>Although not statistically significant, some studies indicate that there may be a slightly increased risk of venous thromboembolism (deep venous thrombosis, pulmonary embolism) associated with the use of progestogen-only preparations. Generally recognized risk factors for venous thromboembolism (VTE) include a positive personal or family history (VTE in a sibling or a parent at a relatively early age), age, obesity, prolonged immobilization, major surgery or major trauma. In<em> </em>case of long-term immobilization it is advisable to discontinue the use of Visanne (in the case of elective surgery at least four weeks in advance) and not to resume treatment until two weeks after complete remobilization.</p><p>&nbsp;</p><p>The increased risk of thromboembolism in the puerperium must be considered.</p><p>&nbsp;</p><p>Treatment should be stopped at once if there are symptoms of an arterial or venous thrombotic event or suspicion thereof.</p><p>&nbsp;</p><p style="margin-left:.25in; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Tumours</u></em></p><p>A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using oral contraceptives (OCs), mainly using estrogen-progestogen preparations. The excess risk gradually disappears during the course of the 10 years after cessation of combined OC (COC) use. Because breast cancer is rare in women under 40 years of age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer. The risk of having breast cancer diagnosed in users of progestogen-only preparations is possibly of similar magnitude to that associated with COC. However, for progestogen-only preparations, the evidence is based on much smaller populations of users and so is less conclusive than that for COCs. These studies do not provide evidence for causation. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in OC users, the biological effects of OCs or a combination of both. The breast cancers diagnosed in users of OCs tend to be less advanced clinically than the cancers diagnosed in those who have never used OCs.</p><p>&nbsp;</p><p>In rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of hormonal substances such as the one contained in Visanne. In isolated cases, these tumours have led to life-threatening intra-abdominal haemorrhages. A hepatic tumour should be considered in the differential diagnosis when severe upper abdominal pain, liver enlargement or signs of intra-abdominal haemorrhage occur in women taking Visanne.</p><p>&nbsp;</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Osteoporosis</u></em></p><p>Changes in bone mineral density (BMD)</p><p>The use of Visanne in adolescents (12 to &lt;18 years) over a treatment period of 12 months was associated with a decrease in bone mineral density (BMD) in the lumbar spine (L2-L4). The mean relative change in BMD from baseline to the end of treatment (EOT) was -&nbsp;1.2% with a range between -6% and 5% (IC 95%: -1.70% and -0.78%, n=103. Repeated measurement at 6 months after the EOT in a subgroup with decreased BMD values showed a trend towards recovery. (Mean relative change from baseline: &ndash;2.3% at EOT and &ndash;0.6% at 6 months after EOT with a range between -9% and 6% (IC 95%: -1.20% and 0.06% (n=60)</p><p>Loss of BMD is of particular concern during adolescence and early adulthood, a critical period of bone accretion. It is unknown if BMD decrease in this population will reduce peak bone mass and increase the risk for fracture in later life. (see sections 4.2 and 5.1)</p><p>&nbsp;</p><p>In patients who are at an increased risk of osteoporosis a careful risk-benefit assessment should be performed before starting Visanne because endogenous estrogen levels are moderately decreased during treatment with Visanne (see section 5.1).</p><p>&nbsp;</p><p>Adequate intake of calcium and Vitamin D, whether from the diet or from supplements, is important for bone health in women of all ages.</p><p>&nbsp;</p><p style="margin-left:.25in; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Other conditions</u></em></p><p>Patients who have a history of depression should be carefully observed and the drug should be discontinued if the depression recurs to a serious degree.</p><p>&nbsp;</p><p>Dienogest generally does not appear to affect blood pressure in normotensive women. However, if a sustained clinically significant hypertension develops during the use of Visanne, it is advisable to withdraw Visanne and treat the hypertension.</p><p>&nbsp;</p><p>Recurrence of cholestatic jaundice and/or pruritus which occurred first during pregnancy or previous use of sex steroids necessitates the discontinuation of Visanne.</p><p>&nbsp;</p><p>Dienogest may have a slight effect on peripheral insulin resistance and glucose tolerance. Diabetic women, especially those with a history of gestational diabetes mellitus, should be carefully observed while taking Visanne.</p><p><strong>&nbsp;</strong></p><p>Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst taking Visanne.</p><p>&nbsp;</p><p>Pregnancies that occur among users of progestogen-only preparations used for contraception are more likely to be ectopic than are pregnancies among users of combined oral contraceptives. Therefore, in women with a history of extrauterine pregnancy or an impairment of tube function, the use of Visanne should be decided on only after carefully weighing the benefits against the risks.</p><p>&nbsp;</p><p>Persistent ovarian follicles (often referred to as functional ovarian cysts) may occur during the use of Visanne. Most of these follicles are asymptomatic, although some may be accompanied by pelvic pain.</p><p>&nbsp;</p><p style="margin-left:17.0pt; text-indent:-17.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Lactose</u></p><p>Each Visanne tablet contains 62.8 mg of lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption who are on a lactose-free diet should consider the amount contained in Visanne.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Note: The prescribing information of concomitant medication should be consulted to identify potential interactions.</p><p>&nbsp;</p><p style="margin-left:.25in; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Effects of other medicinal products on Visanne</u></em></p><p>&nbsp;</p><p>Progestogens including dienogest are metabolized mainly by the cytochrome P450 3A4 system (CYP3A4) located both in the intestinal mucosa and in the liver. Therefore, inducers or inhibitors of CYP3A4 may affect the progestogen drug metabolism.</p><p>&nbsp;</p><p>An increased clearance of sex hormones due to enzyme induction may reduce the therapeutic effect of Visanne and may result in undesirable effects e.g. changes in the uterine bleeding profile.</p><p>&nbsp;</p><p>A reduced clearance of sex hormones due to enzyme inhibition may increase the exposure to dienogest and may result in undesirable effects.</p><p>&nbsp;</p><p style="margin-left:21.3pt; text-indent:-21.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Substances increasing the clearance of sex hormones (diminished efficacy by enzyme-induction), e.g.:</p><p style="margin-left:21.3pt; margin-right:0in">phenytoin, barbiturates, primidone, carbamazepine, rifampicin, and possibly also oxcarbazepine, topiramate, felbamate, griseofulvin, and products containing St. John&rsquo;s wort (<em>Hypericum perforatum).</em></p><p>&nbsp;</p><p>Enzyme induction can already be observed after a few days of treatment. Maximum enzyme induction is generally seen within a few weeks After cessation of drug therapy enzyme induction may be sustained for about 4 weeks.</p><p>&nbsp;</p><p>The effect of the CYP 3A4 inducer rifampicin was studied in healthy postmenopausal women. Co-administration of rifampicin with estradiol valerate/dienogest tablets led to significant decreases in steady state concentrations and systemic exposures of dienogest and estradiol. The systemic exposure of dienogest and estradiol at steady state, measured by AUC(0-24h), were decreased by 83% and 44%, respectively.</p><p style="margin-left:21.3pt; text-indent:-21.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Substances with variable effects on the clearance of sex hormones:</p><p>When co-administered with sex hormones, many combinations of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors, including combinations with HCV inhibitors can increase or decrease plasma concentrations of the progestin. The net effect of these changes may be clinically relevant in some cases.</p><p style="margin-left:21.3pt; text-indent:-21.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Substances decreasing the clearance of sex hormones (enzyme inhibitors)</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:-21.3pt">Dienogest&nbsp;is a substrate of cytochrome P450 (CYP) 3A4.</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:-21.3pt">The clinical relevance of potential interactions with enzyme inhibitors remains unknown.</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:-21.3pt">Concomitant administration of strong CYP3A4 inhibitors can increase plasma concentrations of dienogest.</p><p>Coadministration with the strong CYP3A4 enzyme inhibitor ketoconazole resulted in a 2.9-fold increase of AUC (0-24h) at steady state for dienogest. Concomitant administration of the moderate inhibitor erythromycin increased the AUC (0-24h) of dienogest at steady state by 1.6-fold</p><p style="margin-left:24.0pt; margin-right:0in; text-indent:-24.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Effects of Visanne on other medicinal products</em></p><p>&nbsp;</p><p>Based on <em>in vitro</em> inhibition studies, a clinically relevant interaction of dienogest with the cytochrome P450 enzyme mediated metabolism of other medication is unlikely.</p><p>&nbsp;</p><p style="margin-left:.25in; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Interaction with food.</u></em></p><p>&nbsp;</p><p>A standardized high fat meal did not affect the bioavailability of Visanne.</p><p>&nbsp;</p><p style="margin-left:.25in; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Laboratory tests</u></em></p><p>&nbsp;</p><p>The use of progestogens may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins (e.g. corticosteroid binding globulin and lipid/lipoprotein fractions), parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Changes generally remain within the normal laboratory range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em></p><p>There is limited data from the use of dienogest in pregnant women.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p><strong><u>&nbsp;</u></strong></p><p>Visanne must not be administered to pregnant women because there is no need to treat endometriosis during pregnancy.</p><p>&nbsp;</p><p><em><u>Lactation</u></em></p><p>Treatment with Visanne during lactation is not recommended.</p><p>&nbsp;</p><p>It is unknown wheter dienogest is excreted in human milk. Data in animals have shown excretion of dienogest in rat milk.</p><p>&nbsp;</p><p>A decision must be made whether to discontinue breast-feeding or to abstain from Visanne therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-indent:0in"><em><u>Fertility</u></em></p><p>Based on the available data, ovulation is inhibited in the majority of patients during treatment with Visanne. However, Visanne is not a contraceptive.</p><p>&nbsp;</p><p>If contraception is required a non-hormonal method should be used (See section 4.2).</p><p>&nbsp;</p><p>Based on available data, the menstrual cycle returns to normal within 2 months after cessation of treatment with Visanne.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No effects on the ability to drive and use machines have been observed in users of products containing dienogest.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Presentation of undesireable effects is based on MedDRA.</p><p>The most appropriate MedDRA term is used to describe a certain reaction and its synonyms and related conditions.</p><p>&nbsp;</p><p>Undesirable effects are more common during the first months after the start of treatment with Visanne, and subside with continued treatment. There may be changes in bleeding pattern, such as spotting, irregular bleeding or amenorrhea. The following undesirable effects have been reported in users of Visanne.</p><p>The most frequently reported undesirable effects under treatment with Visanne are headache (9.0%), breast discomfort (5.4%), depressed mood (5.1 %) and acne (5.1 %).</p><p>&nbsp;</p><p>In addition, the majority of patients treated with Visanne experience changes in their menstrual bleeding pattern. Menstrual bleeding patterns were assessed systematically using patient diaries and were analyzed using the WHO 90 days reference period method. During the first 90 days of treatment with Visanne the following bleeding patterns were observed (n=290; 100%): Amenorrhea (1.7%), infrequent bleeding (27.2%), frequent bleeding (13.4%), irregular bleeding (35.2%), prolonged bleeding (38.3%), normal bleeding, i.e. none of the previous categories (19.7%). During the fourth reference period the following bleeding patterns were observed (n=149; 100%): Amenorrhea (28.2%), infrequent bleeding (24.2%), frequent bleeding (2.7%), irregular bleeding (21.5%), prolonged bleeding (4.0%), normal bleeding, i.e. none of the previous categories (22.8%). Changes in menstrual bleeding patterns were only occasionly reported as adverse event by the patients (See adverse event table).</p><p>&nbsp;</p><p>The frequencies of adverse drug reactions (ADRs) by MedDRA system organ classes (MedDRA SOCs) reported with Visanne are summarized in the table below. Within each frequency grouping, undesirable effects are presented in order of decreasing frequency. Frequencies are defined as common (&ge;1/100 to &lt;1/10)<s> </s>and uncommon (&ge;1/1,000 to &lt;1/100). The frequencies are based on pooled data of four clinical trials, including 332 patients (100%).</p><p>&nbsp;</p><p><strong>Table 1, Adverse reactions table, phase III clinical trials, N= 332 </strong></p><table cellspacing="0" cellpadding="0" border="1" style="width:640px"><thead><tr><td style="vertical-align:top; width:1.75in"><p style="margin-left:-5.4pt; margin-right:0in"><strong>&nbsp;System Organ Class (MedDRA)</strong></p></td><td style="vertical-align:top; width:138.0pt"><p><strong>Common</strong></p></td><td style="vertical-align:top; width:3.0in"><p><strong>Uncommon</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top; width:1.75in"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top; width:138.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:3.0in"><p>anemia</p></td></tr><tr><td style="vertical-align:top; width:1.75in"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top; width:138.0pt"><p>weight increase</p></td><td style="vertical-align:top; width:3.0in"><p>weight decrease<br />increased appetite</p></td></tr><tr><td style="vertical-align:top; width:1.75in"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top; width:138.0pt"><p>depressed mood<br />sleep disorder<br />nervousness<br />loss of libido<br />altered mood</p></td><td style="vertical-align:top; width:3.0in"><p>anxiety<br />depression<br />mood swings</p></td></tr><tr><td style="vertical-align:top; width:1.75in"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top; width:138.0pt"><p>headache<br />migraine</p></td><td style="vertical-align:top; width:3.0in"><p>autonomic nervous system imbalance<br />disturbance in attention</p></td></tr><tr><td style="vertical-align:top; width:1.75in"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top; width:138.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:3.0in"><p style="margin-left:0in; margin-right:0in">dry eye</p></td></tr><tr><td style="vertical-align:top; width:1.75in"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top; width:138.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:3.0in"><p>tinnitus</p></td></tr><tr><td style="vertical-align:top; width:1.75in"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top; width:138.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:3.0in"><p style="margin-left:0in; margin-right:0in">unspecific circulatory system disorder<br />palpitations</p></td></tr><tr><td style="vertical-align:top; width:1.75in"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top; width:138.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:3.0in"><p style="margin-left:0in; margin-right:0in">hypotension</p></td></tr><tr><td style="vertical-align:top; width:1.75in"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top; width:138.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:3.0in"><p>dyspnoea</p></td></tr><tr><td style="vertical-align:top; width:1.75in"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top; width:138.0pt"><p>nausea<br />abdominal pain<br />flatulence<br />abdominal distension<br />vomiting<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p></td><td style="vertical-align:top; width:3.0in"><p>diarrhoea<br />constipation<br />abdominal discomfort<br />gastrointestinal inflammation<br />gingivitis</p></td></tr><tr><td style="vertical-align:top; width:1.75in"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td><td style="vertical-align:top; width:138.0pt"><p>acne<br />alopecia<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top; width:3.0in"><p>dry skin<br />hyperhidrosis<br />pruritus<br />hirsutism<br />onychoclasis<br />dandruff<br />dermatitis<br />abnormal hair growth<br />photosensitivity reaction pigmentation disorder</p></td></tr><tr><td style="vertical-align:top; width:1.75in"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top; width:138.0pt"><p>back pain<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p></td><td style="vertical-align:top; width:3.0in"><p>bone pain<br />muscle spasms<br />pain in extremity<br />heaviness in extremities</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table cellspacing="0" cellpadding="0" border="1" style="width:640px"><tbody><tr><td style="vertical-align:top; width:1.75in"><p><strong>&nbsp;System Organ Class </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:138.0pt"><p><strong>Common</strong></p></td><td style="vertical-align:top; width:3.0in"><p><strong>Uncommon</strong></p></td></tr><tr><td style="vertical-align:top; width:1.75in"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top; width:138.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:3.0in"><p>urinary tract infection</p></td></tr><tr><td style="height:135.45pt; vertical-align:top; width:1.75in"><p><strong>Reproductive system and breast disorders </strong></p></td><td style="height:135.45pt; vertical-align:top; width:138.0pt"><p>breast discomfort<br />ovarian cyst<br />hot flushes<br />uterine / vaginal bleeding including spotting</p><p>&nbsp;</p></td><td style="height:135.45pt; vertical-align:top; width:3.0in"><p>vaginal candidiasis<br />vulvovaginal dryness<br />genital discharge<br />pelvic pain<br />atrophic vulvovaginitis<br />breast mass<br />fibrocystic breast disease<br />breast induration<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p></td></tr><tr><td style="height:135.45pt; vertical-align:top; width:1.75in"><p><strong>General disorders and administration site conditions</strong></p></td><td style="height:135.45pt; vertical-align:top; width:138.0pt"><p>asthenic conditions<br />irritability</p></td><td style="height:135.45pt; vertical-align:top; width:3.0in"><p>Oedema</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Decrease of bone mineral density</strong></p><p>In an uncontrolled clinical trial with 111 adolescent women (12 to &lt;18 years) who were treated with Visanne, 103 had BMD measurements. Approximately 72% of these study participants experienced a decrease in BMD of the lumbar spine (L2-L4) after 12 months of use (see section 4.4).</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&nbsp;</strong></p><p><strong>Other Countries:</strong></p><p>Please contact the relevant competent authority</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute toxicity studies performed with dienogest did not indicate a risk of acute adverse effects in case of inadvertent intake of a multiple of the daily therapeutic dose. There is no specific antidote. A daily intake of 20 - 30 mg dienogest (10 to 15 times higher dose than in Visanne) over 24 weeks of use was very well tolerated.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: progestogens; ATC code: G03DB08</p><p>Dienogest is a nortestosterone derivative with no androgenic but rather an antiandrogenic activity of approximately one third of that of cyproterone acetate. Dienogest binds to the progesterone receptor of the human uterus with only 10% of the relative affinity of progesterone. Despite its low affinity to the progesterone receptor, dienogest has a strong progestogenic effect in vivo. Dienogest has no significant androgenic, mineralocorticoid or glucocorticoid activity <em>in vivo</em>.</p><p>&nbsp;</p><p>Dienogest acts on endometriosis by reducing&nbsp; the endogenous production of oestradiol and thereby suppresses the trophic effects of estradiol on both the eutopic and ectopic endometrium. When given continuously, dienogest leads to a hypoestrogenic, hypergestagenic endocrine environment causing initial decidualization of endometrial tissue followed by atrophy of endometriotic lesions.</p><p>&nbsp;</p><p><em><u>Data on efficacy:</u></em></p><p>Superiority of Visanne over placebo was demonstrated in a 3-months study including 198 patients with endometriosis. Endometriosis-associated pelvic pain was measured on a Visual Analog Scale (0-100 mm). After 3 months of treatment with Visanne a statistically significant difference compared to placebo (D = 12.3&nbsp;mm; 95%CI: 6.4 &ndash; 18.1; p&lt;0.0001) and a clinically meaningful reduction of pain compared to baseline (mean reduction = 27.4 mm &plusmn; 22.9) were demonstrated.<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p>After 3 months of treatment,&nbsp; reduction of endometriosis-associated pelvic pain by 50% or more without relevant increase of concomitant pain medication was achieved in 37.3% of patients on Visanne (placebo: 19.8%); a reduction of endometriosis-associated pelvic pain by 75% or more without relevant increase of concomitant pain medication was achieved in 18.6% of patients on Visanne (placebo: 7.3%).</p><p>&nbsp;</p><p>The open-label extension to this placebo-controlled study suggested a continued improvement of endometriosis-associated pelvic pain for a treatment duration of up to 15 months.</p><p>&nbsp;</p><p>The placebo controlled results were supported by the results obtained in a 6 months active-controlled study versus a GnRH agonist including 252 patients with endometriosis.</p><p>&nbsp;</p><p>Three studies including a total of 252 patients who received a daily dose of 2 mg dienogest demonstrated a substantial reduction of endometriotic lesions after 6 months of treatment.</p><p>&nbsp;</p><p>In a small study (n=8 per dose group), a daily dose of 1 mg dienogest has been shown to induce an anovulatory state after 1 month of treatment. Visanne has not been tested for contraceptive efficacy in larger studies.</p><p style="margin-left:0in; margin-right:0in"><s>&nbsp;</s></p><p style="margin-left:0in; margin-right:0in"><em><u>Data on safety</u></em>:</p><p style="margin-left:0in; margin-right:0in">Endogenous estrogen levels are moderately suppressed during treatment with Visanne.</p><p>Currently, long-term data on bone mineral density (BMD) and risk of fractures in users of Visanne are not available. BMD was assessed in 21 adult patients before and after 6 months of treatment with Visanne and there was no reduction of mean BMD.</p><p style="margin-left:0in; margin-right:0in">In 29 patients treated with leuprorelin acetate (LA), a mean reduction of 4.04% &plusmn; 4.84 was noted after the same period (D between groups = 4.29%; 95%CI: 1.93 &ndash; 6.66; p&lt;0.0003).</p><p style="margin-left:0in; margin-right:0in">No significant changes of the mean values of standard laboratory parameters (including haematology, blood chemistry, liver enzymes, lipids and HbA1C) were observed during treatment with Visanne for up to 15 months (n=168).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in"><em><u>Safety in adolescents</u></em></p><p>The safety of Visanne with respect to BMD was investigated in an uncontrolled clinical trial over 12 months in 111 adolescent women (12 to &lt;18 years) with clinically suspected or confirmed endometriosis. The mean relative change in BMD of the lumbar spine (L2-L4) from baseline in the 103 patients with BMD measurement was -1.2 %. In a subset of the patients with decreased BMD a follow-up measurement was performed 6 months after end of treatment and showed an increase in BMD to -0.6%.</p><p>&nbsp;</p><p><em><u>Long-term safety</u></em></p><p>A long-term post-approval observational active surveillance study was conducted to investigate the incidence of first-time occurrence or worsening of clinically relevant depression and occurrence of anemia. A total of 27,840 women with a newly prescribed hormonal therapy for endometriosis were enrolled in the study and followed up for up to 7 years.</p><p>A total of 3,023 women started with a prescription for dienogest 2 mg and 3,371 patients started with other approved endometriosis drugs. The overall adjusted hazard ratio for new occurrences of anemia comparing the dienogest patients with the patients on other approved endometriosis drugs was 1.1 (95% CI: 0.4 &ndash; 2.6). The adjusted hazard ratio for depression risk comparing dienogest and other approved endometriosis drugs was 1.8 (95% CI: 0.3-9.4). A slightly increased risk of depression in dienogest users compared with users of other approved endometriosis drugs could not be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-.1pt">&nbsp;</p><p style="margin-left:24.0pt; margin-right:0in; text-indent:-24.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Absorption</u></em></p><p>&nbsp;</p><p>Orally administered dienogest is rapidly and almost completely absorbed. Peak serum concentrations of 47&nbsp;ng/ml are reached at about 1.5 hours after single ingestion. Bioavailability is about 91%. The pharmacokinetics of dienogest are dose-proportional within the dose range of 1&nbsp;‑&nbsp;8&nbsp;mg.</p><p>&nbsp;</p><p style="margin-left:24.0pt; margin-right:0in; text-indent:-24.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Distribution</u></em></p><p>&nbsp;</p><p>Dienogest is bound to serum albumin and does not bind to sex hormone binding globulin (SHBG) or corticoid binding globulin (CBG).<em> </em>10&nbsp;% of the total serum drug concentration is present as free steroid, 90&nbsp;% is non-specifically bound to albumin.</p><p>&nbsp;</p><p>The apparent volume of distribution (V<sub>d</sub>/F) of dienogest is 40&nbsp;l.</p><p>&nbsp;</p><p style="margin-left:24.0pt; margin-right:0in; text-indent:-24.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Biotransformation</em></p><p>&nbsp;</p><p>Dienogest is completely metabolized by the known pathways of steroid metabolism, with the formation of endocrinologically mostly inactive metabolites. Based on in vitro and in vivo studies, CYP3A4 is the major enzyme involved in the metabolism of dienogest. The metabolites are excreted very quickly so that in plasma unchanged dienogest is the dominating fraction.</p><p>&nbsp;</p><p>The metabolic clearance rate from serum Cl/F is 64&nbsp;ml/min.</p><p>&nbsp;</p><p style="margin-left:24.0pt; margin-right:0in; text-indent:-24.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Elimination</u></em></p><p>&nbsp;</p><p>Dienogest serum levels decrease in two phases. The terminal disposition phase is characterized by a half-life of approximately 9-10 hours. Dienogest is excreted in form of metabolites which are excreted at a urinary to faecal ratio of about 3:1 after oral administration of 0.1&nbsp;mg/kg. The half-life of urinary metabolites excretion is 14 hours . Following oral administration approximately 86% of the dose administered is eliminated within 6 days, the bulk of this amount excreted within the first 24 h, mostly with the urine .</p><p>&nbsp;</p><p style="margin-left:24.0pt; margin-right:0in; text-indent:-24.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Steady-state conditions</u></em></p><p>&nbsp;</p><p>Pharmacokinetics of dienogest are not influenced by SHBG levels. Following daily ingestion drug serum levels increase about 1.24 fold reaching steady-state conditions after 4 days of treatment. The pharmacokinetics of dienogest after repeated administration of Visanne can be predicted from single dose pharmacokinetics.</p><p>&nbsp;</p><p style="margin-left:24.0pt; margin-right:0in; text-indent:-24.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em><u>Pharmacokinetics in Special Population</u></em></p><p style="margin-right:-.1pt">Visanne has not been studied specifically in renally impaired subjects.</p><p style="margin-right:-.1pt">Visanne has not been studied in subjects with hepatic impairment.</p><p style="margin-right:-.1pt"><strong><u>&nbsp;</u></strong></p><p style="margin-right:-.1pt"><strong><u>&nbsp;</u></strong></p><p style="margin-right:-.1pt"><strong><u>&nbsp;</u></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special risks for humans based on conventional studies of repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction. However, it should be borne in mind that sex steroids can promote the growth of certain hormone-dependent tissues and tumours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Crospovidone</p><p>Lactose monohydrate</p><p>Magnesium stearate</p><p>Microcrystalline cellulose</p><p>Potato starch</p><p>Povidone K 25</p><p>Talc</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                

3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original packaging to protect from light.</p><p>Do not store above 30˚C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tablets are contained in blister packs consisting of green transparent films made of polyvinylidene chloride (PVDC) coated polyvinyl chloride (PVC) and metallic foils made of aluminum (mat side hot sealable).</p><p>&nbsp;</p><p>Pack sizes:</p><p>28, 84 and 168 tablets</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG
Leverkusen, Germany.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>